Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Toripalimab with Gemcitabine-Cisplatin in Bladder Cancer
NCT04861584Phase 2Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Jun 2021
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in bladder cancer, sponsored by Southern Medical University Zhujiang Hospital. Started Jun 2021; status: recruiting.
02
Drugs
toripalimab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT04861584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04861584.